Home > Insider Trading > Filing (0000899243-22-009825)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1801395	Paul Blanchfield	C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-03-03	20,653	$0.00	82,573	No	4	A	Direct
Common Stock	Disposition	2022-03-04	3,914	$49.98	78,659	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2022-03-03	11,776	$0.00	11,776	$49.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,776		2032-03-03	No	4	A	Direct

Footnotes

Consists of 6,884 restricted stock units that vest in equal installments over a three-year period and 13,769 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
Includes 932 shares and 659 shares acquired under the LNTH employee stock purchase plan on March 16, 2021 and September 23, 2021, respectively.
The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transactions reported in this Form 4 were effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
The option vests in three equal annual installments beginning on March 3, 2023.